Abstract：
BACKGROUND: 18F -fluorodeoxyglucose (FDG) positron emission tomography (PET) plays an important role in the staging and response assessment of lymphoma patients. Our aim was to explore the predictive relevance of metabolic tumor volume (MTV) and total lesion glycolysis (TLG) in patients with early stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD16 trial.
METHODS: 18F-FDG PET/CT images were available for MTV and TLG analysis in 107 cases from the HD16 trial. We calculated MTV and TLG using three different threshold methods (SUV4.0, SUV41% and SUV140%L), and then performed receiver-operating-characteristic analysis to assess the predictive impact of these parameters in predicting an adequate therapy response with PET negativity after 2 cycles of chemotherapy.
RESULTS: All three threshold methods analyzed for MTV and TLG calculation showed a positive correlation with the PET response after 2 cycles chemotherapy. The largest area under the curve (AUC) was observed using the fixed threshold of SUV4.0 for MTV- calculation (AUC 0.69 [95% CI 0.55-0.83]) and for TLG-calculation (AUC 0.69 [0.55-0.82]). The calculations for MTV and TLG with a relative threshold showed a lower AUC: using SUV140%L AUCs of 0.66 [0.53-0.80] for MTV and 0.67 for TLG [0.54-0.81]) were observed, while with SUV41% an AUC of 0.61 [0.45-0.76] for MTV, and an AUC 0.64 [0.49-0.80]) for TLG were seen.
CONCLUSIONS: MTV and TLG do have a predictive value after two cycles ABVD in early stage Hodgkin lymphoma, particularly when using the fixed threshold of SUV4.0 for MTV and TLG calculation.
BACKGROUND: ClinicalTrials.gov NCT00736320 .
METHODS: 18F-FDG PET/CT images were available for MTV and TLG analysis in 107 cases from the HD16 trial. We calculated MTV and TLG using three different threshold methods (SUV4.0, SUV41% and SUV140%L), and then performed receiver-operating-characteristic analysis to assess the predictive impact of these parameters in predicting an adequate therapy response with PET negativity after 2 cycles of chemotherapy.
RESULTS: All three threshold methods analyzed for MTV and TLG calculation showed a positive correlation with the PET response after 2 cycles chemotherapy. The largest area under the curve (AUC) was observed using the fixed threshold of SUV4.0 for MTV- calculation (AUC 0.69 [95% CI 0.55-0.83]) and for TLG-calculation (AUC 0.69 [0.55-0.82]). The calculations for MTV and TLG with a relative threshold showed a lower AUC: using SUV140%L AUCs of 0.66 [0.53-0.80] for MTV and 0.67 for TLG [0.54-0.81]) were observed, while with SUV41% an AUC of 0.61 [0.45-0.76] for MTV, and an AUC 0.64 [0.49-0.80]) for TLG were seen.
CONCLUSIONS: MTV and TLG do have a predictive value after two cycles ABVD in early stage Hodgkin lymphoma, particularly when using the fixed threshold of SUV4.0 for MTV and TLG calculation.
BACKGROUND: ClinicalTrials.gov NCT00736320 .
摘要：
背景：18F-氟脱氧葡萄糖（FDG）正电子发射断层扫描（PET）在淋巴瘤患者的分期和反应评估中起着重要作用。我们的目的是探讨在德国霍奇金研究组HD16试验中治疗的早期霍奇金淋巴瘤患者中代谢性肿瘤体积（MTV）和总病变糖酵解（TLG）的预测相关性。
方法：18F-FDGPET/CT图像可用于HD16试验的107例患者的MTV和TLG分析。我们使用三种不同的阈值方法(SUV4.0、SUV41%和SUV140%L)计算了MTV和TLG，然后进行接受者操作特征分析，以评估这些参数在预测2个周期化疗后PET阴性的适当治疗反应方面的预测影响。
结果：分析MTV和TLG计算的所有三种阈值方法均显示与2周期化疗后的PET反应呈正相关。使用SUV4.0的固定阈值进行MTV-计算(AUC0.69[95%CI0.55-0.83])和TLG-计算(AUC0.69[0.55-0.82])观察到最大的曲线下面积(AUC)。对于具有相对阈值的MTV和TLG的计算显示了较低的AUC:对于MTV使用0.66[0.53-0.80]的SUV140%LAUC,对于TLG使用0.67[0.54-0.81])。而SUV41%的MTV的AUC为0.61[0.45-0.76]，并且观察到TLG的AUC为0.64[0.49-0.80])。
结论：MTV和TLG在早期霍奇金淋巴瘤中两个周期ABVD后确实具有预测价值，特别是在使用SUV4.0的固定阈值进行MTV和TLG计算时。
背景：ClinicalTrials.govNCT00736320。
方法：18F-FDGPET/CT图像可用于HD16试验的107例患者的MTV和TLG分析。我们使用三种不同的阈值方法(SUV4.0、SUV41%和SUV140%L)计算了MTV和TLG，然后进行接受者操作特征分析，以评估这些参数在预测2个周期化疗后PET阴性的适当治疗反应方面的预测影响。
结果：分析MTV和TLG计算的所有三种阈值方法均显示与2周期化疗后的PET反应呈正相关。使用SUV4.0的固定阈值进行MTV-计算(AUC0.69[95%CI0.55-0.83])和TLG-计算(AUC0.69[0.55-0.82])观察到最大的曲线下面积(AUC)。对于具有相对阈值的MTV和TLG的计算显示了较低的AUC:对于MTV使用0.66[0.53-0.80]的SUV140%LAUC,对于TLG使用0.67[0.54-0.81])。而SUV41%的MTV的AUC为0.61[0.45-0.76]，并且观察到TLG的AUC为0.64[0.49-0.80])。
结论：MTV和TLG在早期霍奇金淋巴瘤中两个周期ABVD后确实具有预测价值，特别是在使用SUV4.0的固定阈值进行MTV和TLG计算时。
背景：ClinicalTrials.govNCT00736320。
